An ambitious biotech with a different perspective on drug discovery.

 

 

ABOUT PROSETTA

Prosetta Biosciences, Inc. is a 12-year old biotechnology company focused on developing novel small-molecule antiviral therapeutics based on over 25 years of basic research on the Cell-Free Protein Synthesizing Systems (CFPSS).

Our CFPSS drug discovery platform allows for identification of small molecule drugs which may be missed with traditional pharma screening methods.

Prosetta has successfully produced highly potent compounds which disrupt or alter the key protein-protein interactions involved with the assembly of viral capsids and display activity against multiple strains of many viral families.

News
Takeda to Study Prosetta Biosciences' CNS Compounds

Takeda Pharmaceutical will partner with Prosetta Biosciences on a feasibility study for possible future co-development of Prosetta’s novel compounds for diseases and disorders of the central nervous system. Read more here.

Prosetta announces closing of private placement with Alger Management and Takeda Pharmaceutical Company, limited, among others.